Organization (Industry)
RIGEL PHARMACEUTICALS INC
ClinicalTrials.gov lists RIGEL PHARMACEUTICALS INC as lead sponsor of 28 trials. It has 15 active development programs and 8 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 6 registered with a 2026 start date. The dashed outline is the pace from the 6 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers RIGEL PHARMACEUTICALS INC: 28 lead-sponsored trials and 2 legal-entity registrations.
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Disease areas (43)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Thrombocytopenia | 7 |
| Hemorrhage | 6 |
| Purpura, Thrombocytopenic, Idiopathic | 6 |
| Arthritis, Rheumatoid | 4 |
| Leukemia, Myeloid, Acute | 4 |
Showing 5 of 43 disease areas.
Trials by start year as sponsor or collaborator (19)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 6 |
| 2025 | 4 |
| 2024 | 4 |
| 2023 | 1 |
| 2022 | 1 |
| 2021 | 4 |
| 2020 | 1 |
| 2019 | 2 |
| 2018 | 1 |
| 2016 | 1 |
Showing 10 of 19 years.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (15)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Fostamatinib Disodium | Purpura, Thrombocytopenic, Idiopathic | Phase 3 | 3 |
| Fostamatinib Disodium | Thrombocytopenia | Phase 3 | 3 |
| Fostamatinib Disodium | Hemorrhage | Phase 3 | 3 |
| Fostamatinib | COVID-19 | Phase 3 | 1 |
| Fostamatinib | Severe Acute Respiratory Syndrome | Phase 3 | 1 |
Showing 5 of 15 active programs.
Approved assets (8)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| CYP3A4, CYP2C8, and CYP2C9 substrates, and hormonal contraceptive | 1 |
| CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates | 1 |
| Olutasidenib | 1 |
| Pralsetinib | 1 |
| Fostamatinib Disodium | 9 |
Showing 5 of 8 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 40% hit target (n=5) | 20% on time (n=5) |
Journals published in (12)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Blood | 2 |
| The Cochrane database of systematic reviews | 2 |
| American journal of hematology | 1 |
| Cancer research | 1 |
| Experimental dermatology | 1 |
Showing 5 of 12 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 494 | 45 | 2025-11-04 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 294,282,000 | 367,024,000 | 33,295,000 |
| 2024 | 179,278,000 | 17,485,000 | 23,380,000 |
| 2023 | 116,882,000 | -25,091,000 | 24,522,000 |
| 2022 | 120,242,000 | -58,573,000 | 60,272,000 |
| 2021 | 149,236,000 | -17,914,000 | 65,237,000 |
| 2020 | 108,621,000 | -29,744,000 | 60,101,000 |
| 2019 | 59,288,000 | -66,894,000 | 52,885,000 |
| 2018 | 44,509,000 | not reported | 46,903,000 |
| 2017 | 4,484,000 | not reported | 46,269,000 |
| 2016 | 20,383,000 | not reported | 63,446,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (15)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-06-11 | Royalty / licensing | 70,000,000 | Sec extracted |
| 2026-05-11 | Royalty / licensing | not disclosed | Sec extracted |
| 2026-04-16 | Royalty / licensing | not disclosed | Sec extracted |
| 2024-09-03 | Royalty / licensing | 10 | Sec extracted |
| 2024-08-02 | Other financing | not disclosed | Edgar offerings |
Showing 5 of 15 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 3 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Rigel Pharmaceuticals, Inc. | South San Francisco, US | FDA |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (14)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| M.D. Anderson Cancer Center | Co sponsors trial with | 2 |
| Government of the United States of America | Co sponsors trial with | 2 |
| Allegheny Health Network | Co sponsors trial with | 1 |
| Washington University in St. Louis | Co sponsors trial with | 1 |
| Holdsworth House Medical Practice | Co sponsors trial with | 1 |
Showing 5 of 14 relationships.
Latest dated events (556)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-09 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-11 | Royalty / licensing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-05-11 | Royalty / licensing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-04-16 | Royalty / licensing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 556 events.
Biomarker capability evidence (154)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ACE | Trial sponsor | Named in trial inclusion criteria |
| AGT | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| CABIN1 | Trial collaborator | Named in trial inclusion criteria |
| CALR | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 154 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, fda warning letters, fda untitled letters, fda recalls, fda import refusals, clia clinical laboratory certificates, and biomarkers this organization publishes on.